Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-07923568 · 1 trial · 2 indications
Cmax was the highest concentration observed directly from data
AUClast was determined using linear/Log trapezoidal method
AUClast + (Clast\*/kel), where Clast\* was the predicted plasma concentration at the last quantifiable time point estimated from the log-linear regression analysis and kel was the terminalphase rate constant.
| Arm | Type | Description |
|---|---|---|
| Healthy subjects | EXPERIMENTAL | One time dose of 4 capsules taken orally. |
| Mild Hepatic impaired subjects | EXPERIMENTAL | One time dose of 4 capsules taken orally. |
| Moderate hepatic impaired subjects | EXPERIMENTAL | One time dose of 4 capsules taken orally |
| Severe Hepatic Impaired Subjects | EXPERIMENTAL | One time dose of 4 capsules taken orally. |
| Name | Type | Description |
|---|---|---|
| PF-07923568 | DRUG | One time dose of 4 capsules taken orally. |
Inclusion Criteria: for healthy volunteers: * BMI of 17.5 to 38.0 kg/m2, inclusive, and a total body weight \>50 kg (110 lb). * Capable of giving signed informed consent. * At screening, no clinically relevant abnormalities identified by a detailed medical history, complete physical examination, in...
PF-07923568 is an investigational small molecule being developed by Pfizer for liver diseases, specifically studied in the context of hepatic impairment. It is currently in Phase 1 clinical development and is not approved by the FDA.
PF-07923568 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 1 clinical development for liver diseases.
PF-07923568 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. A Phase 1 study has been completed to evaluate how the drug is processed in participants with different levels of liver function.
PF-07923568 has one completed Phase 1 clinical trial, identified as NCT05857644. This study compared how the drug is processed in participants with different levels of loss of liver function versus healthy participants. The trial enrolled 28 participants in the United States.
The specific molecular target or mechanism of action for PF-07923568 has not been disclosed. It is a small molecule being studied for its effects in liver diseases, with a focus on how it is processed in individuals with hepatic impairment.